CML-292 Chronic Myeloid Leukemia Reduces Survival in Elderly Patients (Age ≥ 75 Years Old): An International Multicenter Retrospective Studydoi:10.1016/S2152-2650(23)01129-1Erez Halperin MDAlon Rozental MDChiya Leibovitch MDMerav Barzilai MD
[4] A study by Gugliotta et al that examined the use of imatinib in patients aged 65 years or older found that the response to imatinib was not affected by age. [5] In the IRIS (International Randomized Study of Interferon and STI571) study, imatinib produced a higher rate of complete...
You know, sometimes there’s the argument that, well, they don’t improve survival. Well, no, you know, with imatinib you’ve already reached near normal life expectancy, so, now we’re looking beyond just the survival benefit. And so, I prefer a second-generation TKI, and bosutinib ...
After the introduction of tyrosine kinase inhibitors (TKIs), the annual rate of progression from CML-CP to AP or BP dramatically decreased to 1–1.5% from more than 20% [1, 2]. However, the prognosis for adult patients with de novo or secondary CML-BP remains poor; median survival is ...
(G) Survival rate of mice following combined treatment with imatinib and SBI-0206965. Survival rates were determined (n = 8). Comparison of survival rates was performed using the log-rank test. Pathological contribution of p16- and p21-expressing megakaryocytes in patients with CML In line with...
The International Randomized Study of Interferon and STI571 (IRIS) trial found an estimated cumulative com- plete cytogenetic response rate (CCyR) and overall survival of 87% and 89%, respectively, among 553 patients who received first-line imatinib for five years[4]. Despite the impressive ...
The 8-year survival for patients with a CCI ≥5 was 48%, compared with 91% for those with a CCI of 2.8 Thus, the presence of comorbidities is an important element of the management of patients with CML. The patient Our patient is a 59-year-old construction worker with an 8.5 pack-...
[Although] there was a difference looking at the [survival] numbers, I didn’t feel very strongly that you would necessarily need to [reduce]. I was a little surprised that there weren’t more AEs in the 45-mg arm, the general age and cardiovascular profile of these patients. Jabbour: ...
Shepherd P, Suffolk R, Halsey J, Allan N (1995) Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol ...
Age atdiagnosis,ySexTreatmentprior toimatinibBestresponseprior toimatinibDiseasedurationpriortoimatinib,moDiseasephaseatstartingimatinibBestresponsetoimatinibTimetodetectionofabnormality,moMDSSurvivalfromdiagnosis,moInitialkaryotypeKaryotypeat bestresponse priorto imatinibKaryotypeprior toimatinibFirst karyotypewith ...